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 Introduction 
 Stroke is associated with high mortality in the acute 
phase, ranging from 13 to 27% in the first month and 
from 18 to 33% in the first 3 months  [1] . Yet several pop-
ulation-  [2, 3] and hospital-based  [4, 5] studies have 
shown a 10% annual risk of death even many years after 
the initial stroke, i.e. twice that expected in the general 
population of the same age and sex. Predictors of long-
term mortality for ischaemic stroke are ischaemic heart 
disease, atherothrombosis  [6] , cardio-embolic stroke  [7] , 
age and diabetes  [4] .
 The SINPAC (Società Inter-regionale Piemonte e Val-
le d’Aosta per le Cerebrovasculopatie) – a group of Italian 
neurologists (see appendix) – has conducted a prospec-
tive study on acute cerebrovascular patients managed in 
neurological departments in north-western Italy during 
1999. Methods and the clinical features of the population 
have already been described in detail  [8] . We now report 
the results of the 6-month and 5-year follow-up of pa-
tients admitted for a first-ever ischaemic stroke classified 
according to the Oxfordshire Community Stroke Project 
(OCSP) classification   [9] . We aimed to determine the 
variables at admission, during hospital stay, at discharge 
and at 6 months that independently predict survival at 5 
years.
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 Abstract 
 Background: Few studies have addressed predictors of long-
term mortality after first-ever ischaemic stroke.  Methods: We 
prospectively collected data on 361 consecutive patients ad-
mitted to 18 neurology departments in Italy for a first-ever 
ischaemic stroke in 1999, categorized according to the Ox-
fordshire Community Stroke Project (OCSP) classification. 
Age, gender, risk factors, previous vascular disease, in-hospi-
tal complications, stroke severity, functional status, therapy 
and living place at admission, discharge and after 6 months 
were recorded. Follow-up was available for 97% patients at 5 
years.  Results: Survival probability was 91% (95% CI = 88–94) 
at 1 month, 84% (80–88) at 6 months and 64% (58–69) at 5 
years. Mortality was higher for the TACI (total anterior circula-
tion infarct) group compared to the other categories (p  ! 
0.0001). Hazard ratios for 5-year mortality in the final model 
were: 5.4 for age  6 65 years (p  ! 0.0001), 2.8 for TACI (p  ! 
0.0001), 2.7 for previous vascular disease (p  ! 0.01) and 1.9 for 
cardio-embolic risk according to the TOAST risk stratification 
(p  ! 0.05).  Conclusions: Our study extends the prognostic 
value of the OCSP classification to 5-year survival. 
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 Methods 
 This is a hospital-based prospective study involving 18 neurol-
ogy departments (16 first-referral) of the Piedmont and the Aosta 
Valley Regions (north-western Italy). Patients were enrolled if 
older than 25 years and consecutively admitted to each depart-
ment with stroke or transient ischaemic attack (TIA), either first-
ever or recurrent, from May 1 to July 31, 1999. Stroke and TIA 
were defined according to WHO criteria  [10] ; subarachnoid 
haemorrhage was excluded. 
 Data were collected on a specifically designed form, including 
demographics, details of onset, emergency room management, 
risk factors, course and management during hospital stay and de-
tails of discharge. Further details on methods and design of the 
study are described in a previous article  [8] . The choice of treat-
ment and diagnostic work-up was left to each physician’s judge-
ment. At the time of the study, none of the participating centres 
had a stroke unit. 
 Of the 604 patients enrolled, 443 had an ischaemic stroke , 64 
a haemorrhagic stroke and 97 a TIA. Here we investigate the long-
term follow-up of the 361 patients with a first-ever ischaemic 
stroke, including 9 without CT scan accepted according to the 
Guy’s Hospital Stroke Diagnostic Score  [11] . Follow-up evalua-
tions were scheduled at 6 months and 5 years after onset, either 
by clinical visit or by telephone interviews with patients, family 
members or caregivers. For patients not traced by the centres (47 
at 6 months and 80 at 5 years), a postal follow-up was conducted 
through their municipality of residence: in this case, only the vital 
status was available. Vital status was known for 359 patients (99%) 
at 30 days, 357 (99%) at 6 months and 350 (97%) at 5 years; of the 
11 not traced, 64% were males, the mean age was 71  8 14 years, 
the mean Glasgow Coma Scale (GCS) score at admission was 14 
 8 3, without any statistical difference with those who completed 
the follow-up (57% males, mean age 70  8 12, mean GCS 14  8 3). 
The Kaplan-Meier method was used to calculate survival curves 
and the log-rank test to assess differences between groups. Pa-
tients were divided according to OCSP classification into partial 
anterior circulation infarction (PACI), lacunar infarction (LACI), 
total anterior circulation infarction (TACI) and posterior circula-
tion infarction (POCI). The other predictors were divided into the 
variables described below. 
 Pre-Admission Variables and Risk Factors 
 We assessed gender, age, living place, home therapy, smoking, 
hypertension, embolic cardiopathy according to the TOAST risk 
stratification  [12] , diabetes, hyperlipaemia, alcohol abuse, obesity, 
internal carotid artery occlusion/stenosis  1 50%, previous TIA 
and previous vascular disease (defined as a history of peripheral 
arteriopathy, deep venous thrombosis or pulmonary embolism).
 In-Hospital Variables 
 In-hospital variables were GCS, modified Rankin Scale (MRS) 
and Scandinavian Stroke Study Group scale (SSS)  [13] scores at 
admission, medical and neurological complications. Medical 
complications were defined as any of the following: urinary, chest 
or other infections, fractures, pressure sores, deep venous throm-
bosis, pulmonary embolism, acute pulmonary oedema, gastro-
intestinal bleeding or ulcer, myocardial infarction, cardiac fail-
ure, arrhythmias, peripheral arterial ischaemia, acute renal fail-
ure or painful shoulder. Neurological complications were defined 
as any of the following: epileptic seizure, haemorrhagic transfor-
mation, recurrent stroke, progressing stroke, depression or de-
mentia.
 Variables at Discharge 
 MRS score, destination and prescribed therapy were consid-
ered as variables at discharge.
 Six-Month Variables 
 At the 6-month follow-up, MRS score, ongoing therapy and 
current living place were the variables assessed.
 Variables were operationally defined in a previous paper  [8, 
14] . Missing data were handled in ways that always gave conserva-
tive estimates of each risk. Given the large number of variables 
that could significantly explain our outcomes, we decided to fix 
the   error at 0.01. Multivariate analysis (Cox proportional haz-
ard model) was performed including the centre and the variables 
significant in the univariate analysis. For this purpose, the vari-
ables were dichotomized as follows: age,  ! 65 versus  6 65 years; 
embolic risk cardiopathy, medium-to-high versus low; MRS, 1–3 
versus 4–5; clinical syndrome, TACI versus all the others; destina-
tion at discharge, institution versus any other. Other variables 
were dichotomized as yes/no. Since GCS, SSS and MRS are asso-
ciated, but only MRS was available at admission, discharge and 6 
months, MRS was run in the multivariate model. Statistical anal-
yses were performed with the SAS package version 8.2  [15] .
 Results 
 The number of strokes per centre ranged from 7 to 40 . 
Survival probabilities were: 91% (95% CI = 88–94) at 30 
days from the event, 84% (80–88) at 6 months, 81% (77–
85) at 1 year, 78% (73–82) at 2, 73% (68–77) at 3, 69% 
(64–74) at 4 and 64% (58–69) at the 5-year follow-up 
( fig. 1 ). According to OCSP classification criteria, 125 pa-
tients (35%) had PACI, 109 (30%) LACI, 72 (20%) TACI 
and 55 (15%) POCI. Survival probabilities at 6 months 
and 5 years were significantly lower for TACI (p  ! 0.0001) 
compared to the other categories ( table 1 and  fig. 2 ). 
When considering only patients surviving the first 6 
months, TACI was still predictive (p  ! 0.01;  fig. 3 ).
 Table 1 shows the survival probabilities at 6 months 
and 5 years for the other prognostic factors.
 Pre-Admission Variables and Risk Factors 
 Older age, living in an institution before stroke, car-
dio-embolic risk and history of vascular disease were sig-
nificant prognostic factors at both 6 months and 5 
years. 
 Stroke Characteristics and In-Hospital Variables 
 Stroke severity at onset (evaluated either by GCS, SSS 
or MRS) and medical and neurological complications 
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during hospital stay were predictive of a worse survival. 
The first multivariate model, including centre, and those 
predictive pre-admission variables, risk factors, stroke 
characteristic and in-hospital variables significant after 
univariate analysis, yielded the following hazard ratios 
for 6-month mortality: 4.2 for TACI (p  ! 0.0001), 3.0 for 
MRS at admission (p  ! 0.01), 2.9 for neurological compli-
cations (p  ! 0.005), 2.1 for cardio-embolic risk (p  ! 0.01) 
and 2.1 for living in an institution before stroke (p  ! 0.05). 
Age was not retained in the model. The corresponding 
values for 5-year mortality were: 3.9 for age  6 65 years 
(p  ! 0.0001), 3.4 for TACI (p  ! 0.0001), 2.1 for neurologi-
cal complications (p  ! 0.01), 2.0 for previous vascular dis-
ease (p  ! 0.05), 1.6 for cardio-embolic risk (p  ! 0.01) and 
1.6 for medical complications (p  ! 0.05). The values of the 
likelihood ratio test of the multivariate model were 110.4 
(p  ! 0.0001) at 6 months and 128.7 (p  ! 0.0001) at 5 
years.
 Variables at Discharge 
 Thirty-two patients died during their hospital stay. 
Among the 329 survivors, better functional status at dis-
charge as estimated by a lower score on the MRS scale and 
discharge to the previous living place or to a rehabilita-
tion unit were associated with longer survival at both fol-
low-up times. The final multivariate models, which in-
clude the at-discharge predictors significant after univar-
iate analysis, are shown in  table 2 . The values of the 
likelihood ratio test of the multivariate model were 38.5 
(p  ! 0.0001) at 6 months and 71.8 (p  ! 0.0001) at 5 years, 
respectively. When considering only patients surviving 
the first 6 months, TACI was still an independent predic-
tor (hazard ratio adjusted for the variables significant af-
ter univariate analysis = 2.6, p = 0.01). 
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 Fig. 1. Five-year overall survival for 361 patients with a first-ever 
ischaemic stroke. 
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 Fig. 2. Five-year survival by OCSP classification subtype. Sur-
vival times are computed from the date of stroke for PACI, LACI, 
TACI and POCI. TACI versus others, p  ! 0.0001; all the other 
comparisons are not significant. 
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 Fig. 3. Five-year survival by OCSP classification subtype for pa-
tients surviving the first 6 months. Survival times are computed 
from 6 months after stroke. Five-year  survival percentages and 
95% confidence intervals were 79.5 (71.7–87.3) for PACI, 77.2 
(69.0–85.4) for LACI, 79.0 (67.4–90.6) for POCI and 58.4 (42.3–
74.8) for TACI. TACI versus others, p  ! 0.01; all the other com-
parisons are not significant. 
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Six-month 
survival, % 
p value Five-year 
survival, % 
p value
Pre-admission variables and risk factors (n = 361)
Gender
Female (154, 43%) 82.5 (76.4–88.6) n.s. 60.4 (52.6–68.2) n.s.
Male (207, 57%) 85.4 (80.5–90.3) 65.9 (59.2–72.6)
Age
≤64 years (101, 28%) 94.1 (89.4–98.8) 87.8 (81.3–94.3)
65–74 years (114, 32%) 85.9 (79.4–92.4) <0.0005 66.1 (57.1–75.1) <0.0001
75–84 years (102, 28%) 79.3 (71.5–87.1) 49.4 (39.6–59.2)
≥85 years (44, 12%) 67.4 (53.3–81.5) 33.8 (19.1–48.5)
Living place 
Home (332, 92%) 85.8 (82.1–89.5) <0.001 65.6 (60.3–70.9) <0.001
Institution (29, 8%) 65.3 (47.9–82.7) 39.9 (21.7–58.1)
Home therapy 
Antiplatelet drugs 
No (284, 79%) 84.4 (78.8–87.4) n.s. 66.1 (60.4–71.8) n.s.
Yes (77, 21%) 83.1 (74.7–91.5) 53.7 (42.1–65.3)
Oral anticoagulants
No (346, 96%) 84.0 (80.1–87.9) n.s. 63.4 (58.1–68.7) n.s.
Yes (15, 4%) 86.7 (69.5–100) 66.7 (42.8–90.6)
Antihypertensive drugs
No (209, 58%) 84.2 (79.3–89.1) n.s. 61.0 (54.1–67.9) n.s.
Yes (152, 42%) 84.1 (78.2–90.0) 66.9 (59.3–74.5)
Oral hypoglycaemic drugs
No (327, 91%) 84.0 (80.1–87.9) n.s. 64.3 (59.0–69.6) n.s.
Yes (34, 9%) 85.3 (73.3–97.3) 56.7 (39.5–74.0)
Smoking
No (258, 71%) 82.1 (77.4–86.8) n.s. 60.0 (53.9–66.1) n.s.
Yes (103, 29%) 89.2 (83.1–95.3) 72.5 (63.7–81.3)
Hypertension
No (147, 40%) 81.5 (75.2–87.8) n.s. 59.3 (51.1–67.5) n.s.
Yes (214, 60%) 85.9 (81.2–90.6) 66.4 (59.9–72.9)
Embolic risk cardiopathy
Low (220, 61%) 90.9 (87.2–94.6) 71.1 (65.0–77.3)
Medium (45, 12%) 70.9 (57.6–84.2) <0.0001 56.1 (41.2–71.0) <0.0001
High (96, 27%) 74.6 (65.8–83.4) 48.0 (37.7–58.3)
Diabetes
No (297, 82%) 84.8 (80.7–88.9) n.s. 64.8 (59.3–70.3) n.s.
Yes (64, 18%) 81.3 (71.7–90.9) 57.9 (45.6–70.3)
Hyperlipaemia
No (316, 88%) 83.4 (79.3–87.5) n.s. 62.5 (57.0–68.0) n.s.
Yes (45, 12%) 88.9 (79.7–98.1) 70.7 (57.2–84.2)
Alcohol abuse
No (334, 93%) 84.0 (80.1–87.9) n.s. 62.8 (57.5–68.1) n.s.
Yes (27, 7%) 85.2 (71.9–98.5) 73.0 (55.8–90.3)
Obesity
No (303, 84%) 85.4 (81.5–89.3) n.s. 62.6 (56.9–68.3) n.s.
Yes (58, 16%) 77.6 (66.8–88.4) 68.3 (56.2–80.5)
Atherosclerosis of ICA 
No (321, 89%) 83.7 (79.6–87.8) n.s. 63.7 (58.4–69.0) n.s.
Yes (40, 11%) 87.5 (77.3–97.7) 61.8 (45.7–77.9)
Previous TIA
No (315, 87%) 83.1 (79.0–87.2) n.s. 62.5 (57.0–68.0) n.s.
Yes (46, 13%) 91.3 (83.1–99.5) 70.7 (57.2–84.2)
Previous vascular disease
No (338, 94%) 85.4 (81.7–89.1) <0.01 65.6 (60.5–70.7) <0.0005
Yes (23, 6%) 65.2 (45.8–84.6) 34.8 (15.4–54.2)
Table 1. Kaplan-Meier estimates of probability of survival at 6 months and 5 years after first ischaemic stroke 
for patients according to the study variables (univariate analysis)
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Six-month 
survival, % 
p value Five-year 
survival, % 
p value
Stroke characteristics and in-hospital variables (n = 361)
ER GCS score
≥14 (260, 72%) 93.8 (90.9–96.7) 74.6 (69.2–80.1)
10–13 (56, 16%) 71.9 (60.5 – 83.3) <0.0001 44.6 (31.6–57.6) <0.0001
≤9 (40, 11%) 32.4 (16.7 – 48.1) 17.5 (05.7–29.3)
MRS score at admission
1–3 (176, 49%) 95.4 (92.3–98.5) <0.0001 72.7 (66.0–79.4) <0.0001
4–5 (185, 51%) 73.4 (66.9–79.9) 54.8 (47.4–62.3)
SSS score at admission 
≥50 (127, 35%) 98.4 (96.2–100) 74.6 (66.8–82.4)
41–49 (75, 21%) 88.0 (80.6–95.5) <0.0001 67.2 (56.4–78.0) <0.0001
≤40 (159, 44%) 70.9 (63.8–78.0) 53.1 (45.1–61.1)
OCSP classification
LACI (109, 30%) 96.3 (92.8–99.8) 73.2 (64.6–81.8)
POCI (55, 15%) 89.1 (80.9–97.3) <0.0001 70.4 (58.3–82.6) <0.0001
PACI (125, 35%) 89.5 (84.0–95.0) 71.1 (62.9–79.3)
TACI (72, 20%) 52.8 (41.2–64.4) 30.8 (20.0–41.6)
Medical complications
No (298, 83%) 89.9 (86.4–93.4) <0.0001 68.9 (63.4–74.4) <0.0001
Yes (63, 17%) 56.9 (44.6–69.3) 37.9 (25.6–50.3)
Neurological complications
No (330, 91%) 87.5 (84.0–91.0) <0.0001 66.6 (61.3–71.9) <0.0001
Yes (31, 9%) 47.5 (29.7–65.3) 30.6 (14.1–47.1)
Variables at discharge (n = 329)
MRS score 
1–3 (241, 73%) 95.4 (92.9–98.0) <0.0005 74.0 (68.3–79.7) 0.001
4–5 (88, 27%) 84.1 (76.5–91.7) 57.5 (46.7–68.3)
Destination 
Home/rehabilitation (292, 89%) 94.2 (91.5–96.9) <0.0005 72.3 (67.0–77.6) <0.001
Institutional care (37, 11%) 78.4 (65.1–91.7) 49.3 (32.6–66.0)
Therapy with antiplatelet drugs/oral anticoagulants
No (23, 7%) 92.5 (89.6–95.4) n.s. 64.1 (44.1–84.1) n.s.
Yes (306, 93%) 91.3 (79.7–100) 70.2 (65.7–74.7)
Therapy with antihypertensive drugs
No (168, 51%) 92.6 (88.5–96.7) n.s. 68.8 (61.6–76.1) n.s.
Yes (161, 49%) 92.3 (88.2–96.4) 70.8 (63.6–78.1)
Six-month variables (n = 257)
MRS score
1–3 (221, 86%) 77.7 (72.0–83.4) n.s.
4–5 (36, 14%) 63.7 (47.0–80.4)
Therapy with antiplatelet drugs/oral anticoagulants
No (21, 8%) 68.4 (47.4–89.4) n.s.
Yes (236, 92%) 76.4 (70.7–82.1)
Therapy with antihypertensive drugs
No (139, 54%) 71.4 (63.6–79.2) n.s.
Yes (118, 46%) 80.7 (73.5–88.0)
Rehabilitation
No (228, 89%) 73.6 (67.7–79.5) n.s.
Yes (29, 11%) 92.9 (83.3–100)
Living place
As before hospital admission (231, 90%) 75.8 (70.1–81.5) n.s.
Institution (26, 10%) 75.3 (58.0–92.5)
Survival data in parentheses indicate 95% confidence intervals. n.s. = Non-significant; ICA = internal carotid artery; ER = 
emergency room.
Table 1 (continued)
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 Six-Month Variables 
 Twenty-five patients died between discharge and 6 
months. Information on the 6-month variables was not 
available for 47 of the 304 survivors. There was no sig-
nificant difference between patients with and without 
available information for age, living place, cardio-embol-
ic risk, previous vascular disease, GCS at admission, and 
MRS scores at admission and discharge. Patients with 
missing information had more medical (21 vs. 10%, p  ! 
0.05) and neurological (21 vs. 10%, p  ! 0.05%) complica-
tions. None of the variables considered at 6 months were 
predictive for 5-year survival.
 Discussion 
 In our cohort of first-ever ischaemic stroke patients 
hospitalized in mostly first-referral (16/18) neurological 
departments, the 6-month and 5-year survival rates were 
84 and 64%; the major prognostic predictors of 5-year 
mortality were age  6 65 years, TACI stroke subtype, pre-
vious vascular disease and cardio-embolic risk.
 Although many studies have estimated the short-term 
prognosis of first-ever ischaemic stroke, much less infor-
mation is available for longer periods. Comparison with 
our study is hampered by differences in the case mix 
(first-ever vs. recurrent stroke), ascertainment (popula-
tion- vs. hospital-based studies) and setting (neurological 
vs. medical wards). Two population-based surveys fol-
lowed first-ever ischaemic patients for 5 years or more 
 [16, 17] with a 5-year survival of 47–59%. In two hospital-
based series, survival was 64% at 4 years  [18] and 51% at 
5 years  [5] ; however, the latter cohort was probably biased 
(age  6 65 years, Medicare subjects, ICD 436 included, 
first-in-the-year, not first-ever stroke). All these studies 
found a survival rate lower than our cohort. These differ-
ences may be real or depend on the calendar years of as-
certainment (improvement of prognosis in recent years) 
or on a possible selection bias (inclusion of healthier and 
younger individuals in our neurological-ward-based 
study). Some studies, in fact, have shown that patients 
treated by neurologists have lower mortality rates  [19, 
20] .
 We used OCSP criteria to classify all our patients ac-
cording to their clinical syndrome. This is a simple, easy 
and reliable method of categorizing acute ischaemic 
stroke patients and is predictive for short-term outcome 
 [4, 21, 22] . A large European study including 2,740 first-
ever ischaemic strokes  [21] found a significantly higher 
28-day and 3-month mortality for TACI, followed by 
PACI, POCI and LACI. TACI subjects had a fivefold risk 
of dying and a threefold risk of disability and handicap 3 
months after stroke, compared to LACI. Another study 
 [22] found a 6-month survival of 45% (TACI), 90% 
(LACI), 93% (POCI) and 96% (PACI). Others  [23–25] re-
ported a worse survival for TACI, still 2–3 years after 
stroke. We found a similar pattern still evident 5 years 
after stroke, when survival was only 31% for TACI and 
much higher for the other three groups (70–73%). LACIs 
have been associated with a better prognosis in many 
studies  [26, 27] . Our survey suggests that a better long-
term prognosis is not confined to LACI, since PACI and 
POCI also performed fairly better than TACI with a more 
than double survival rate, even after adjusting for the oth-
er major predictors. 
 We found an independent predictive value for the 
TOAST category of high-to-medium embolic risk cardi-
opathy in accordance with two large hospital-based stud-
ies from Germany  [28] and the Netherlands  [4] . Cardio-
vascular events other than cerebrovascular ones are the 
first cause of death in stroke survivors after the acute 
phase  [2, 3, 29, 30] ; a meta-analysis by Touzé et al.  [31] 
found a 2% yearly risk of myocardial infarction and non-
stroke vascular death after a TIA or stroke. Since a his-
Table 2. Six-month and 5-year survival in 361 patients with a first ischaemic stroke: final multivariate model 
including pre-admission variables and risk factors, in-hospital variables and variables at discharge 
Six-month 
hazard ratio
p value Five-year 
hazard ratio
p value
Age ≥65 years 4.7 <0.05 5.4 <0.0001
TACI 3.0 <0.05 2.8 <0.001
Previous vascular disease 2.4 n.s. 2.7 <0.01
Medium-to-high embolic risk cardiopathy 4.1 <0.005 1.9 <0.005
 Long-Term Stroke Survival Is Worse in 
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tory of vascular disease was also retained in our multi-
variate 5-year survival models, there is reason to think 
that non-cerebral cardiovascular diseases may influence 
the long-term prognosis of stroke patients besides stroke 
severity characteristics.
 Bae et al.  [18] found that medical complications were 
still an independent predictor of mortality 4 years after a 
first or recurrent ischaemic stroke in a cohort admitted 
to a neurological department. In our study, mortality for 
patients who experienced either neurological or medical 
in-hospital complications was significantly higher than 
for those who did not in the univariate analysis, but not 
in the final model. 
 In conclusion, our study confirms the predictive value 
of OCSP classification at 5 years, with TACI as a strong 
predictive factor, associated with age, cardio-embolic risk 
and history of prior vascular disease. Prognostic stratifi-
cation with OCSP could enhance comparability of pa-
tients in long-term trials and survival studies. Our study 
suffers from the selection bias inherent to a neurological-
ward-based study; however, we collected consecutive pa-
tients from different centres (mostly first-referral) which 
makes our sample more representative of the general 
population, and only 3% of patients were lost to follow-
up. Furthermore 42% of strokes hospitalized in the same 
area and year were admitted to neurology wards  [8] . In 
addition, our employment of a hospital series allowed us 
to correlate long-term prognosis with many clinical pre-
dictors not available in population studies.
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